The relationship between the plasma concentration of blonanserin, and its plasma anti-serotonin 5-HT 2A activity/anti-dopamine D 2 activity ratio and drug-induced extrapyramidal symptoms

Psychiatry and Clinical Neurosciences

Volumn 66, Issue 2, 2012, Pages 146-152

  Suzuki, Hidenobu ^a   Gen, Keishi ^b  

^a Tanzawa Hospital   (Japan)

^b Seimo Hospital   (Japan)

Author keywords

Anti serotonin 5 HT 2A activity anti dopamine D 2 activity ratio; blonanserin; DIEPSS; drug induced extrapyramidal symptoms; plasma concentration

Indexed keywords

BIPERIDEN; BLONANSERIN; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CORRELATION ANALYSIS; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG INDUCED EXTRAPYRAMIDAL SYMPTOMS SCALE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; RADIORECEPTOR ASSAY; RATING SCALE; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PIPERIDINES; RECEPTORS, DOPAMINE D2; RECEPTORS, SEROTONIN, 5-HT2; SCHIZOPHRENIA;

EID: 84863395479     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/j.1440-1819.2011.02311.x     Document Type: Article

References (15)

1. Ochi T, Sakamoto M, Minamida A, et al,. Syntheses and properties of the major hydroxy metabolites in humans of blonanserin AD-5423, a novel antipsychotic agent. Bioorg. Med. Chem. Lett. 2005; 15: 1055-1059. (Pubitemid 40458647)
2. 2A activity. Hum. Psychopharmacol. 2010; 25: 342-346.
3. 2 activity. Jpn. J. Clin. Psychopharmacol. 2001; 4: 241-249 (in Japanese).
4. Inada T,. Evaluation and diagnosis of drug-induced extrapyramidal symoptoms. In:, Yagi G, (ed.). Commentary on the DIEPSS and Guide to Its Usage. Seiwa Publishers, Tokyo, 1996; 11-60 (in Japanese).
5. Inada T, Yagi G, Gardos G,. Inter-rater reliability of the drug-induced extrapyramidal symptoms scale (DIEPSS). Abstracts of 20th Collegium Internationale Neuropsycho-Pharmacologicum, Melbourne, Australia, 1996; 23-27. 1996.
6. Oka M, Noda Y, Ochi Y, et al,. Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties. J. Pharmacol. Exp. Ther. 1993; 264: 158-165. (Pubitemid 23309197)
7. Ohoyama K, Yamamura S, Hamaguchi T, et al,. Effect of novel atypical antipsychotic, blonanserin, on extracellular neurotransmitter level in rat prefrontal cortex. Eur. J. Pharmacol. 2011; 653: 47-57.
8. Yang J, Bahk WM, Cho HS, et al,. Efficacy and tolerability of blonanserin in the patients with schizophrenia: A randomized, double-blind, risperidone-compared trial. Clin. Neuropharmacol. 2010; 33: 169-175.
9. Garcia E, Robert M, Peris F, Nakamura H, Sato N, Terazawa Y,. The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: A randomized, double-blind, placebo-controlled, multicentre study. CNS Drugs 2009; 23: 615-625.
10. Murasaki M,. Clinical evaluation of blonanserin for schizophrenia-A randomized controlled study comparing blonanserin with haloperidol. Jpn. J. Clin. Psychopharmacol. 2007; 10: 2059-2079 (in Japanese).
11. 2Aantagonism. Jpn. J. Clin. Psychopharmacol. 2008; 11: 817-833 (in Japanese).
12. Murasaki M,. Preclinical and clinical features of blonanserin. Jpn. J. Clin. Psychopharmacol. 2008; 11: 855-868 (in Japanese).
13. Meltzer HY, Nash JF,. Effects of antipsychotic drugs on serotonin receptors. Pharmacol. Rev. 1991; 43: 587-604.
14. Meltzer HY, Li Z, Kaneda Y, Ichikawa J,. Serotonin receptors: Their key role in drugs to treat schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003; 27: 1159-1172. (Pubitemid 37464960)
15. Meltzer HY, Matsubara S, Lee JC,. Classification of typical and atypical antipsychotic durgs on the basis of dopamine D-1, D-2 and serotonin 2 pki values. J. Pharmacol. Exp. Ther. 1989; 251: 238-246.